NCT07424365 Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
| NCT ID | NCT07424365 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Mild Cognitive Impairment (MCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-05-19 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-05-19 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study plans to learn more about how stimulating the vagus nerve through gentle electrical stimulation applied to the ear can affect decision-making, problem-solving, and other thinking abilities. This process, called transcutaneous auricular vagus nerve stimulation (taVNS), could help improve brain function in both healthy individuals and people with Parkinson's disease (PD).
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18-65. 2. Ability to sign informed consent. 3. Ability to follow written and verbal instructions. 4. For the PD group, a clinical diagnosis of Parkinson's disease without severe motor or cognitive impairments. Exclusion Criteria: 1. Current uncontrolled and/or clinically significant medical condition. 2. Abnormal ear anatomy or active ear infection. 3. Electronic medical implants, such as pacemakers, cochlear prosthesis, neuro-stimulators. 4. Uncorrected visual impairments that would interfere with task performance. (6) Other significant diseases or disorders that might impair study participation.
Contact & Investigator
Cristin Welle, PhD
PRINCIPAL INVESTIGATOR
Dept. of Neurosurgery, School of Medicine, University of Colorado Anschutz Medical Campus
Frequently Asked Questions
Who can join the NCT07424365 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Mild Cognitive Impairment (MCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07424365 currently recruiting?
Yes, NCT07424365 is actively recruiting participants. Contact the research team at elise.carter@cuanschutz.edu for enrollment information.
Where is the NCT07424365 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT07424365 clinical trial?
NCT07424365 is sponsored by University of Colorado, Denver. The principal investigator is Cristin Welle, PhD at Dept. of Neurosurgery, School of Medicine, University of Colorado Anschutz Medical Campus. The trial plans to enroll 80 participants.